Zacks Investment Research lowered shares of KemPharm (NASDAQ:KMPH) from a buy rating to a hold rating in a report released on Wednesday morning, Zacks.com reports.
According to Zacks, “KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders, which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE, United States. “
A number of other research firms have also issued reports on KMPH. ValuEngine upgraded shares of KemPharm from a sell rating to a hold rating in a report on Thursday, August 1st. HC Wainwright assumed coverage on shares of KemPharm in a report on Wednesday, June 19th. They issued a buy rating and a $3.00 target price on the stock. Finally, Oppenheimer reduced their target price on shares of KemPharm from $8.00 to $3.00 and set an outperform rating on the stock in a report on Thursday, May 23rd. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company has an average rating of Buy and a consensus target price of $2.42.
NASDAQ:KMPH opened at $0.89 on Wednesday. The firm has a market cap of $23.06 million, a price-to-earnings ratio of -0.36 and a beta of 1.39. The company’s 50-day moving average is $1.30 and its two-hundred day moving average is $1.67. KemPharm has a 12-month low of $0.71 and a 12-month high of $5.47.
KemPharm (NASDAQ:KMPH) last released its earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.42) by $0.09. As a group, equities analysts predict that KemPharm will post -1.23 earnings per share for the current year.
Large investors have recently added to or reduced their stakes in the business. Wedbush Securities Inc. purchased a new position in shares of KemPharm during the 1st quarter worth about $72,000. BlackRock Inc. lifted its holdings in shares of KemPharm by 25.0% during the 4th quarter. BlackRock Inc. now owns 90,426 shares of the specialty pharmaceutical company’s stock worth $161,000 after acquiring an additional 18,079 shares during the period. Geode Capital Management LLC lifted its holdings in shares of KemPharm by 136.7% during the 4th quarter. Geode Capital Management LLC now owns 171,047 shares of the specialty pharmaceutical company’s stock worth $304,000 after acquiring an additional 98,775 shares during the period. Northern Trust Corp lifted its holdings in shares of KemPharm by 34.0% during the 4th quarter. Northern Trust Corp now owns 43,445 shares of the specialty pharmaceutical company’s stock worth $78,000 after acquiring an additional 11,014 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in shares of KemPharm by 134.5% during the 2nd quarter. Vanguard Group Inc. now owns 1,337,571 shares of the specialty pharmaceutical company’s stock worth $2,341,000 after acquiring an additional 767,100 shares during the period. Institutional investors own 30.11% of the company’s stock.
KemPharm Company Profile
KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder.
Read More: Street Name
Get a free copy of the Zacks research report on KemPharm (KMPH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.